Similarly, in triple negative breast cancer mice model AT-3, Verbubrugge et al. have demonstrated that CD137 and CD40 agonist antibodies associated with RT were an effective regimen to slow tumor growth, but it was unable to cure mice. This evidence concerns the gene TNFRSF9 and neoplasm.